Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 EPS by 9c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q1 EPS of $0.11, $0.09 better than the analyst estimate of $0.02. Revenue for the quarter came in at $137.7 million versus the consensus estimate of $131.07 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Edgewell stock surges on report of rejected takeover bid
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval